IDEXX Laboratories, Inc. ( IDXX ) NASDAQ Global Select

Cena: 645.55 ( 1.97% )

Aktualizacja 08-22 22:00
NASDAQ Global Select
Branża: Medical - Diagnostics & Research
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

IDEXX Laboratories, Inc. opracowuje, produkuje i dystrybuuje produkty i usługi przede wszystkim na rynki towarzyszące zwierząt weterynaryjnych, zwierząt gospodarskich i drobiu, nabiału i testowania wody na całym świecie. Firma działa za pośrednictwem CAG; Produkty jakości wody; LPD; i inne segmenty. Zapewnia produkty diagnostyczne weterynaryjne w zakresie opieki, w tym instrumenty, materiały eksploatacyjne i zestawy testowe szybkiego testu; weterynaryjne usługi diagnostyczne i konsultacyjne laboratoryjne; praktyka zarządzania i diagnostyczne systemy i usługi obrazowania dla lekarzy weterynarii; oraz monitorowanie zdrowia, testowanie materiałów biologicznych oraz laboratoryjne instrumenty diagnostyczne zwierząt i usługi dla społeczności badawczej. Firma oferuje również produkty diagnostyczne i monitorujące zdrowie dla zwierząt gospodarskich, drobiu i nabiału; produkty, które testują wodę dla różnych zanieczyszczeń mikrobiologicznych; oraz elektrolity i analizatory gazów krwi oraz SARS-COV-2 RT-PCR, które są stosowane na rynku diagnostyki medycznej ludzkiej opieki; Chemia w klinicznej, chemia krwi i moczu, hematologia i analizy DX uszywczy; Zestawy testowe Snap Szybkie testy. Ponadto zapewnia testy colilert, colilert-18 i kolisury, które wykrywają obecność całkowitej grupy coli i E. coli w wodzie; Enterolelert, Pseudalelert, Filta-Max i Filta-Max Xpress, Legioolert i Quanti Tayt; Oprogramowanie weterynaryjne i usługi dla niezależnych klinik weterynaryjnych i grup korporacyjnych. Firma sprzedaje swoje produkty poprzez marketing, obsługę klienta, sprzedaż i techniczne grupy usług, a także poprzez niezależnych dystrybutorów i innych sprzedawców. Idexx Laboratories, Inc. został włączony w 1983 roku i ma siedzibę w Westbrook, Maine.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 11 000
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98.975
Ilość akcji: Brak danych
Debiut giełdowy: 1991-06-21
WWW: https://www.idexx.com
CEO: Mr. Jonathan J. Mazelsky
Adres: One IDEXX Drive
Siedziba: 04092 Westbrook
ISIN: US45168D1046
Wskaźniki finansowe
Kapitalizacja (USD) 51 647 034 085
Aktywa: 3 350 766 000
Cena: 645.55
Wskaźnik Altman Z-Score: 16.9
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 53.8
Ilość akcji w obrocie: 99%
Średni wolumen: 591 724
Ilość akcji 80 004 700
Wskaźniki finansowe
Przychody TTM 3 844 817 000
Zobowiązania: 1 732 712 000
Przedział 52 tyg.: 356.14 - 688.12
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: 12.0
P/E branży: 31.3
Beta: 1.357
Raport okresowy: 2025-10-30
WWW: https://www.idexx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Sharon E. Underberg Executive Vice President, General Counsel, & Corporate Secretary 881 053 1961
Mr. Jonathan J. Mazelsky President, Chief Executive Officer & Director 2 768 770 1961
Mr. Brian P. McKeon Chief Financial Officer, Executive Vice President & Treasurer 1 395 155 1962
Mr. Michael J. Lane Executive Vice President and GM of Reference Laboratories & Information Technology 1 171 099 1969
Mr. John Hart Senior Vice President of Global Operations 0 0
Mr. Jeffery D. Chadbourne Senior Vice President of Commercial Finance & Sales Operations 0 1976
Dr. Martin Smith Ph.D. Executive Vice President & Chief Technology Officer 0 1969
Mr. Ken Grady Senior Vice President & Chief Information Officer 0 0
Mr. George J. Fennell Senior Vice President & Chief Revenue Officer 0 1969
Mr. Michael P. Johnson Executive Vice President & Chief Human Resources Officer 0 1978
Lista ETF z ekspozycją na akcje IDEXX Laboratories, Inc.
Symbol ETF Ilość akcji Wartość
VOO 2 282 627 1 224 264 165
VO 1 774 715 951 850 643
QQQ 1 650 102 944 006 853
IVV 1 023 417 546 821 928
SPY 977 615 561 178 491
VUG 911 177 488 700 672
VOT 654 955 351 278 564
IWP 569 625 304 356 456
XLV 551 147 315 764 826
IHI 398 484 212 914 163
IWF 324 981 173 640 756
IWR 304 810 162 863 153
QUAL 279 952 160 157 739
RSP 269 540 154 201 138
GSPX.L 266 163 107 638 733
QQQM 255 585 146 217 622
VHT 252 497 135 424 240
CBUC.DE 206 614 96 574 512
CSSPX.MI 201 454 94 162 364
SXR8.DE 201 454 94 162 364
CSPX.AS 201 454 94 162 364
CSP1.L 201 454 81 469 604
CSPX.L 201 454 107 638 733
EDMU.DE 180 746 84 483 383
EDMU.SW 180 746 96 574 512
OM3L.DE 180 746 84 483 383
EEDG.L 180 746 73 095 317
EEDS.L 180 746 96 574 512
IWDG.L 173 063 69 988 346
FIW 163 332 86 892 624
SPHQ 158 981 90 951 440
IWLE.DE 149 735 69 988 346
IVE 137 832 73 645 145
SWDA.L 130 988 52 972 779
IWDA.AS 130 988 61 225 805
IWDD.AS 130 988 69 988 346
SWDA.MI 130 988 61 225 805
IWDA.L 130 988 69 988 346
EUNL.DE 130 988 61 225 805
U127.L 125 588 71 450 223
LEMA.L 125 588 71 450 223
E127.L 125 588 54 144 831
SCHG 124 179 71 016 426
SPLG 118 362 67 740 481
NQSE.DE 114 723 53 623 139
VUSD.L 109 018 58 470 714
VUAA.L 109 018 58 470 714
VUSA.AS 109 018 51 202 804
VUSA.L 109 018 44 308 522
VUAA.MI 109 018 51 202 804
VUSA.DE 109 018 51 202 804
VUSA.MI 109 018 51 202 804
VONG 103 079 55 285 390
ITOT 102 744 54 897 184
CNX1.L 100 360 40 586 282
CSNDX.SW 100 360 53 623 139
CNDX.L 100 360 53 623 139
SXRV.DE 100 360 46 909 522
GSLC 99 099 53 576 883
VV 93 723 50 267 393
SPYV 88 205 50 745 148
SCHX 80 894 46 130 760
DUHP 80 128 42 813 191
TQQQ 75 462 40 320 101
IUSV 69 490 37 129 213
SGWS.L 64 130 25 934 555
ESGU 63 459 33 906 630
IWB 62 328 33 302 503
SCWS.SW 59 729 25 934 555
SUSW.L 55 485 25 934 555
2B7K.DE 55 485 25 934 555
IS31.DE 54 961 25 689 701
DFAC 53 348 28 504 369
SUWU.SW 48 538 25 934 555
SUWS.L 48 538 25 934 555
2B7J.DE 48 538 22 687 549
SUWG.L 48 538 19 629 346
MVUS.L 48 080 19 444 021
IBCK.DE 48 080 22 473 350
SPMV.L 48 080 25 689 701
SPMD.L 48 080 25 689 701
IYH 47 992 25 642 790
IXJ 46 855 25 035 230
SCHB 46 393 26 441 013
IUHE.AS 45 197 21 125 567
JQUA 42 363 22 634 974
IMCG 42 082 22 484 853
IUHC.L 39 538 21 125 567
IHCU.L 39 538 15 989 519
QDVG.DE 39 538 18 480 646
VWRP.L 39 412 16 018 340
VWRL.AS 39 412 18 510 749
VWRL.L 39 412 16 018 340
VWCE.DE 39 412 18 510 749
VWRA.L 39 412 21 138 232
VWRD.L 39 412 21 138 232
VGWL.DE 39 412 18 510 749
SUSA 39 010 20 843 527
QYLD 38 332 20 481 170
QQXT 37 508 19 954 256
USAC.PA 37 081 18 332 003
LYYB.DE 37 081 18 332 003
USA.PA 37 081 18 332 003
SUAP.L 35 345 14 293 668
EGMW.L 35 241 14 251 876
EEWD.L 35 241 18 829 770
EDMW.DE 35 241 16 472 283
EEWG.L 35 241 14 251 876
EMND.DE 35 241 16 472 283
QQEW 34 833 18 531 156
FHLC 34 378 19 475 137
PABU 31 890 17 039 128
IUSA.DE 31 235 14 599 545
IUSA.L 31 235 12 631 577
IUSA.AS 31 235 14 599 545
IDUS.L 31 235 16 689 009
AVUS 31 014 17 742 799
QLD 30 667 16 385 684
3SUR.DE 30 580 14 293 668
NULG 29 835 13 833 296
SAUA.MI 27 726 12 959 554
QDVR.DE 26 752 12 504 101
36B6.DE 26 752 12 504 101
SUUS.L 26 752 10 818 591
SRIL.AS 26 752 14 293 668
SUAS.L 26 752 14 293 668
XAMB.DE 25 956 12 819 507
WESE.PA 25 956 12 819 507
MWSH.DE 25 956 12 819 507
EXXT.DE 25 588 11 960 096
ISPE.L 24 275 9 817 064
GPSA.L 24 255 9 808 827
SLUS.DE 24 255 11 337 018
SASU.L 24 255 12 959 554
SDUS.L 24 255 12 959 554
SGAS.DE 24 255 11 337 018
IWV 23 108 12 346 846
ACWI 23 007 12 293 069
RSPH 22 574 12 914 359
QQQE 22 403 11 970 146
FXH 22 185 11 802 420
WHCA.AS 20 650 9 651 955
WHCS.AS 20 650 11 033 327
CBUF.DE 20 650 9 651 955
LYTR.DE 20 144 10 038 485
C099.DE 20 144 10 038 485
ONEQ 19 379 10 978 203
VOOV 18 653 10 004 350
EWSP.L 18 373 7 430 339
ESGV 17 560 9 418 130
I50D.AS 16 378 0
I500.AS 16 378 0
I500.L 16 378 0
IWFQ.L 16 091 6 507 176
IWQU.L 16 091 8 597 368
IS3Q.DE 16 091 7 520 977
SPTM 15 486 8 874 076
FQAL 14 932 8 458 978
AHYQ.DE 14 446 7 198 965
IBCF.DE 14 200 6 637 340
IUSE.L 14 200 6 637 340
DSI 14 025 7 493 806
XSP.TO 13 647 10 782 244
KNOW 13 117 0
QQQI 12 849 6 853 271
XQQ.TO 12 766 10 086 223
DFAU 12 710 6 791 080
MWRD.MI 12 654 6 281 218
VONE 12 534 6 722 485
IUQF.L 11 949 4 832 318
IUQA.L 11 949 6 384 524
QDVB.DE 11 949 5 585 181
IUQD.L 11 949 6 384 524
FNDX 11 868 6 753 428
UMDV.AS 11 786 6 297 566
FTC 11 597 6 169 604
QGRW 11 565 6 179 295
PBUS 11 447 6 548 714
ANXU.L 11 221 6 383 913
HNDX.DE 11 221 5 591 830
ANX.PA 11 221 5 591 830
6AQQ.DE 11 221 5 591 830
ANXG.L 11 221 483 771 659
IVV.AX 11 178 9 897 845
PAWZ 10 922 5 835 733
XUS.TO 10 414 8 227 502
SP5C.L 10 143 5 770 612
SP5C.PA 10 143 5 054 624
SP5G.L 10 143 4 372 957
LSPX.L 10 143 437 295 779
SP5L.L 10 143 4 372 957
LYSPH.SW 10 143 4 698 576
SP5H.PA 10 143 5 054 624
LSPU.L 10 143 5 770 612
SPHC.MI 10 143 5 054 624
LYP2.DE 10 143 5 054 624
6TVM.DE 10 143 5 054 624
LYPS.DE 10 143 5 054 624
ETFSP500.WA 10 143 21 609 024
AVLV 10 104 5 780 397
IXJ.AX 9 953 8 812 604
OMFL 9 851 5 635 658
IDWR.L 8 996 4 806 700
IWRD.L 8 996 3 638 095
IQQW.DE 8 996 4 204 901
IWRD.AS 8 996 4 204 901
LWCR.DE 8 820 4 435 101
LWCR.PA 8 820 4 435 101
VGVE.DE 8 743 4 106 350
VHVG.L 8 743 3 553 444
VDEV.L 8 743 4 689 220
VHVE.L 8 743 4 689 220
VGVF.DE 8 743 4 106 350
VEVE.L 8 743 3 553 444
IMCB 8 435 4 506 925
SSO 8 190 4 375 998
ILCG 8 181 4 371 339
BBUS 7 544 4 030 834
BIBL 7 518 4 016 942
SDWD.L 7 098 3 792 384
SAWD.L 7 098 3 792 384
SNAW.DE 7 098 3 317 578
S6DW.DE 7 098 3 317 578
USCA 6 708 3 837 579
FEX 6 498 3 456 936
VTHR 6 275 3 365 533
URTH 6 192 3 308 396
VNRA.DE 6 158 2 892 245
VDNR.L 6 158 3 302 781
VNRT.L 6 158 2 502 814
VNRT.DE 6 158 2 892 245
VNRG.L 6 158 2 502 814
VNRA.L 6 158 3 302 781
SCHK 6 061 3 455 194
500.PA 6 054 3 016 927
500U.L 6 054 3 444 275
H1D5.DE 6 054 3 016 927
AUM5.DE 6 054 3 016 927
100D.L 5 861 252 685 652
L100.L 5 861 252 685 652
100H.L 5 861 3 334 472
100H.PA 5 861 2 920 748
PTNQ 5 777 3 086 708
USCL 5 737 3 065 258
EUSA 5 684 3 037 225
SPXL 5 562 2 971 832
IBCH.DE 5 558 2 597 826
IWDE.L 5 558 2 597 826
XHE 5 518 3 256 462
QFLR 5 216 2 786 960
GPIQ 5 088 2 750 776
PTLC 5 080 2 714 294
USXF 5 040 2 692 827
GSEW 4 758 2 572 365
NRAM.PA 4 647 2 310 140
AVMV 4 476 2 560 674
XYLD 4 457 2 381 419
UPGD 4 270 2 442 824
XHC.TO 4 014 3 171 365
UPRO 3 981 2 127 088
SPUS 3 870 2 067 779
CATH 3 780 2 019 691
VFQY 3 750 2 011 275
XUU.TO 3 713 2 933 734
IYY 3 694 1 973 710
QUS 3 576 2 065 935
SPYX 3 456 1 979 215
CSUS.SW 3 433 1 834 120
CSUS.L 3 433 1 834 120
SXR4.DE 3 433 1 604 488
CU1.L 3 433 1 388 209
PRF 3 373 1 929 659
DFSU 2 852 1 523 852
GUSA 2 715 1 467 837
IHVV.AX 2 713 2 402 412
SUSL 2 700 1 544 643
LSAF 2 463 1 316 005
RWL 2 416 1 382 169
QVML 2 411 1 379 308
DCOR 2 385 1 274 329
PTL 2 289 1 223 035
FINW.L 2 242 1 275 531
LYPD.DE 2 242 1 117 269
JHML 2 241 1 141 856
TMFC 2 189 0
CFA 2 173 1 161 055
IGUS.L 2 158 872 522
HLAL 2 121 871 221
QDVC.DE 2 088 975 905
IUSF.L 2 088 844 356
IUSZ.L 2 088 1 115 575
INAA.L 2 053 830 067
IDNA.L 2 053 1 096 696
INAA.SW 2 053 1 096 696
IQQN.DE 2 053 959 390
IWDC.SW 2 016 875 340
CURE 1 999 1 068 085
TOLL 1 913 1 094 408
NUSI 1 812 784 596
AVLC 1 764 1 009 166
CRBN 1 744 931 934
XSUS.TO 1 722 1 360 526
IWLD.AX 1 722 1 524 746
CFO 1 700 908 327
TILT 1 694 905 121
LESU.DE 1 687 885 832
USSG 1 634 934 795
GPIX 1 617 874 214
QLC 1 505 804 136
QDPL 1 437 767 803
CDX 1 436 767 116
FAD 1 436 763 952
IUSC.SW 1 428 620 206
AVSU 1 402 802 070
MODL 1 377 735 744
IWQE.MI 1 371 640 594
ISPY 1 363 728 264
SIZE 1 330 710 535
STRV 1 323 706 892
V3AL.L 1 273 682 760
V3AB.L 1 273 517 389
NTSX 1 233 658 804
RSPA 1 169 668 773
R1GR.L 1 168 624 150
DFVX 1 159 619 265
SPYI 1 148 612 308
IQSU 1 102 588 809
EGV2.DE 1 092 546 908
SMTC.L 1 092 624 378
CSH2.PA 1 092 546 908
CSH2.L 1 092 47 315 250
JMID 1 082 578 123
EQAL 1 078 616 713
IHWL.AX 1 074 950 974
ETHO 1 068 570 643
USNZ 1 047 598 978
QQA 1 022 584 675
IQQQ 995 531 638
XWD.TO 988 780 806
GGUS 962 520 095
XUSR.TO 929 733 988
WPAB.SW 904 482 843
WPAB.AS 904 482 843
WPAD.AS 904 482 843
EPS 875 467 521
SHE 870 499 177
RXL 848 453 094
WEBA.DE 818 338 660
IWFS.L 804 325 185
IWSZ.L 804 429 639
IS3T.DE 804 375 848
KOKU 769 439 937
XQLT.TO 737 581 918
XVV 708 405 039
AVMC 690 394 742
OALC 688 393 597
HCMT 598 319 517
FNDB 558 311 998
IGWD.L 555 224 264
XBAL.TO 554 437 646
XUH.TO 548 313 595
QQMG 531 303 779
BLES 529 282 649
QYLG 493 263 414
SAWI.AS 483 258 012
CBUY.DE 483 225 709
CRTC 475 271 742
SPXT 471 251 660
PBP 430 245 998
HQGO 419 239 705
MEDI 404 231 124
AFLG 391 208 012
IUS 382 218 538
DXUV 356 190 214
AEJ.L 330 187 745
AEJ.PA 330 164 450
LASP.DE 330 164 450
AEJL.L 330 14 227 310
NBDS 327 0
QNXT 319 170 482
DEUS 311 177 919
DUBS 305 162 964
QQQG 281 150 141
TOK 274 146 455
STXG 274 146 400
QWLD 262 150 435
VLU 258 148 433
SPUU 252 134 646
SZNE 249 133 043
LSEQ 240 137 301
NZAC 237 135 941
ESG 231 123 425
GLOF 221 117 850
EGUS 220 125 859
GEQT.TO 204 161 176
MFUS 204 116 706
ONOF 191 102 053
ONEO 182 104 636
GGRO.TO 180 141 995
MMTM 170 97 046
ESGG 140 74 803
GBAL.TO 121 95 727
QARP 114 65 218
SPMV 112 64 074
NVIR 105 56 103
SPXE 104 55 568
SPXN 102 54 499
SPGM 100 57 335
PHDG 94 53 776
IUME.AS 88 46 911
XYLG 85 45 416
QRMI 83 44 347
XMAG 78 41 676
XRMI 68 36 333
NULC 51 23 646
SQEW 46 24 578
QHDG 45 24 043
WLDX.MI 38 18 801
NTSX.L 30 15 915
NTSX.MI 30 15 915
INRO 27 14 302
WDMF.AX 27 23 907
GCNS.TO 25 20 061
XTR.TO 22 12 693
JCTR 18 9 617
QCLR 13 6 946
QTR 12 6 411
NZUS 8 4 589
XCLR 5 2 671
XTR 3 1 602
SPES.L 0 170 911 210
ESGU.L 0 4 390 959
EQSG.L 0 310 907 267
FWRG.L 0 80 016 059
P500.DE 0 38 489 190
ESGW.DE 0 213 115
EQCH.SW 0 30 291 428
EQGB.L 0 2 818 786 986
G500.L 0 3 319 408 930
PSRF.L 0 10 585 519
MXUS.L 0 5 123 142
SPXD.L 0 43 927 403
SPXS.L 0 43 927 403
EQQQ.MI 0 32 684 378
NESG.L 0 5 217 345
SPXP.L 0 3 336 681 626
IGDA.L 0 853 375
ESGS.L 0 333 532 901
ESGG.L 0 18 475 249
XLVS.L 0 2 935 228
EQL.TO 0 2 974 250
D500.DE 0 38 489 190
PRUS.L 0 139 358
ESPB.L 0 331 806 371
EQAC.SW 0 37 302 417
IE00BYML9W36.SG 0 38 489 190
SPEQ.L 0 2 250 045
MXWO.L 0 4 039 479
EQQD.L 0 4 093 093
6PSA.DE 0 122 105
SPED.L 0 2 250 045
SC0J.DE 0 3 539 392
EQQU.L 0 37 302 417
FTWD.DE 0 922 998
PXS.TO 0 8 687
EQQQ.DE 0 32 684 378
EQQQ.L 0 2 833 454 337
IE00B3YCGJ38.SG 0 38 489 190
PAUS.L 0 2 969 073
ESGW.L 0 243 226
SPXS.MI 0 38 489 190
E500.DE 0 38 379 627
XLVP.L 0 222 957 038
QQC.TO 0 2 709 737
SC0H.DE 0 4 488 897
EQEU.DE 0 0
EQQS.L 0 4 093 093
MXWS.L 0 306 834 836
SPXD.SW 0 43 927 403
QQC-F.TO 0 2 866 745
MXUD.L 0 5 123 142
SPEX.L 0 170 911 210
ESGU.DE 0 3 847 358
Wiadomości dla IDEXX Laboratories, Inc.
Tytuł Treść Źródło Aktualizacja Link
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. zacks.com 2025-05-15 13:11:13 Czytaj oryginał (ang.)
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion. seekingalpha.com 2025-05-14 18:35:10 Czytaj oryginał (ang.)
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year? Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year. zacks.com 2025-05-14 14:41:31 Czytaj oryginał (ang.)
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on. businesswire.com 2025-05-13 18:30:00 Czytaj oryginał (ang.)
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-05-01 14:36:17 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2025-05-01 14:35:25 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago. zacks.com 2025-05-01 12:40:23 Czytaj oryginał (ang.)
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increased demand for its tests and equipment. reuters.com 2025-05-01 12:21:46 Czytaj oryginał (ang.)
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories,” said Jay Mazelsky, President and Chief Executive Officer. “Customers have been askin. businesswire.com 2025-05-01 10:30:00 Czytaj oryginał (ang.)
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar. zacks.com 2025-04-30 14:35:40 Czytaj oryginał (ang.)
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-29 14:50:57 Czytaj oryginał (ang.)
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025. zacks.com 2025-04-29 14:21:11 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-24 15:08:53 Czytaj oryginał (ang.)
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock? IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities. zacks.com 2025-04-21 13:35:41 Czytaj oryginał (ang.)
IDEXX (IDXX) Surges 10.0%: Is This an Indication of Further Gains? IDEXX (IDXX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com 2025-04-10 10:50:37 Czytaj oryginał (ang.)
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-04-09 14:45:33 Czytaj oryginał (ang.)
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-04 17:15:45 Czytaj oryginał (ang.)
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com 2025-04-04 13:55:40 Czytaj oryginał (ang.)
IDEXX Laboratories to Release 2025 First Quarter Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website,. businesswire.com 2025-04-03 17:30:00 Czytaj oryginał (ang.)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. zacks.com 2025-04-02 13:55:56 Czytaj oryginał (ang.)
Should You Hold IDEXX Stock in Your Portfolio for Now? IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising. zacks.com 2025-02-18 10:50:25 Czytaj oryginał (ang.)
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March. businesswire.com 2025-02-13 16:00:00 Czytaj oryginał (ang.)
IDEXX Laboratories And Its Real Value IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years. seekingalpha.com 2025-02-10 13:27:02 Czytaj oryginał (ang.)
Why Idexx Labs Stock Rocketed Higher This Week Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. fool.com 2025-02-07 09:09:14 Czytaj oryginał (ang.)
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage. seekingalpha.com 2025-02-06 16:31:03 Czytaj oryginał (ang.)
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers. Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street. barrons.com 2025-02-03 13:31:00 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2025-02-03 13:26:14 Czytaj oryginał (ang.)
IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices. investopedia.com 2025-02-03 13:22:29 Czytaj oryginał (ang.)
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-02-03 12:30:42 Czytaj oryginał (ang.)
Idexx: Q4 EPS, Revenue Beat Forecast Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million. fool.com 2025-02-03 11:06:09 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago. zacks.com 2025-02-03 10:41:23 Czytaj oryginał (ang.)
Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to the vet clinic. reuters.com 2025-02-03 09:57:11 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. “IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally,” said Jay Mazelsky, President and Chief Executive Officer. "The Company is on the front end of a new wave of major innovation. In Q4, we began shipping the IDEXX inVue Dx™ Cellular Analyzer, our transformational sli. businesswire.com 2025-02-03 08:30:00 Czytaj oryginał (ang.)
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock? IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities. zacks.com 2025-01-27 12:11:14 Czytaj oryginał (ang.)
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma. zacks.com 2025-01-24 11:01:16 Czytaj oryginał (ang.)
IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2024 Earnings Snapshot through a link on. businesswire.com 2025-01-16 18:15:00 Czytaj oryginał (ang.)
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check. zacks.com 2025-01-15 12:41:32 Czytaj oryginał (ang.)
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-26 12:46:11 Czytaj oryginał (ang.)
SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX Sustainability Roundtable Inc. announced Synopsys, IDEXX, and Juniper Networks as winners of the 2024 SBER Awards for standout leadership in sustainability globenewswire.com 2024-12-19 12:09:00 Czytaj oryginał (ang.)
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025 One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities. fool.com 2024-12-13 10:45:00 Czytaj oryginał (ang.)
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. zacks.com 2024-12-11 14:01:21 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. Thes. businesswire.com 2024-12-09 09:30:00 Czytaj oryginał (ang.)
Should You Hold IDEXX Stock in Your Portfolio for Now? IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising. zacks.com 2024-11-22 13:15:19 Czytaj oryginał (ang.)
IDEXX Announces CFO Transition WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX's Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Co. businesswire.com 2024-11-21 09:30:00 Czytaj oryginał (ang.)
IDEXX Laboratories Q3: Weak End-Market Demand Continues I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. seekingalpha.com 2024-11-10 21:50:02 Czytaj oryginał (ang.)
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. fool.com 2024-11-06 06:11:00 Czytaj oryginał (ang.)
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today. fool.com 2024-11-05 11:53:00 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2024-10-31 15:59:07 Czytaj oryginał (ang.)
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points inclu. businesswire.com 2024-10-31 15:15:00 Czytaj oryginał (ang.)
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68. benzinga.com 2024-10-31 14:55:09 Czytaj oryginał (ang.)
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments. zacks.com 2024-10-31 14:10:27 Czytaj oryginał (ang.)
Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-10-31 12:36:22 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago. zacks.com 2024-10-31 10:40:21 Czytaj oryginał (ang.)
IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners. reuters.com 2024-10-31 10:01:34 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company reports revenues of $976 million for the third quarter of 2024, an increase of 7% as reported and 6% organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and 6% organic, and Water revenue growth of 13% as reported and organic. CAG Diagnostics recurring revenue growth of 7% as repor. businesswire.com 2024-10-31 08:30:00 Czytaj oryginał (ang.)
Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com 2024-10-28 12:21:45 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy? Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-24 15:05:37 Czytaj oryginał (ang.)